Zeta Surgical
AI- and computer-vision-powered navigation and robotics for neurosurgery and targeted neurotherapeutics.
Website: https://www.zetasurgical.com/
Cover Block
Open sources
| Field | Value |
|---|---|
| Company | Zeta Surgical |
| Tagline | AI- and computer-vision-powered navigation and robotics for neurosurgery and targeted neurotherapeutics [TechCrunch, March 2022] |
| Headquarters | Boston, United States [TechCrunch, March 2022] |
| Founded | 2018 [TechCrunch, March 2022] |
| Stage | Seed [TechCrunch, March 2022] |
| Business model | Hardware + Software |
| Industry | Healthtech |
| Technology | AI / Machine Learning [TechCrunch, March 2022] |
| Geography | North America |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (3+): José María Amich, Raahil Sha, William Gormley [TechCrunch, March 2022] |
| Funding label | Seed |
| Total disclosed | $5.45 million across confirmed pre-seed and seed rounds [TechCrunch, March 2022] |
Links
Open sources
- Website: https://www.zetasurgical.com/
What an Investor Needs First
PUBLIC Zeta Surgical builds AI- and computer-vision-guided navigation and robotics for neurosurgery and neurotherapeutics, and it merits investor attention because the company is trying to move high-precision cranial guidance beyond the traditional operating room into faster-deploying clinical settings [TechCrunch, March 2022] [Healthcare Discovery, July 2026]. Founded in Boston in 2018, the company emerged from stealth in March 2022 with a $5.2 million seed round after an earlier $250,000 pre-seed, a sequence that put public financing around its point-of-care neuronavigation thesis relatively early in the product life cycle [TechCrunch, March 2022] [PR Newswire, March 2022].
The core platform centers on markerless, real-time image guidance that aligns preoperative imaging to patient anatomy without conventional fiducial markers, with products spanning the Zeta Navigation System for cranial procedures and the Zeta TMS Navigation System for navigated transcranial magnetic stimulation [TechCrunch, March 2022] [Design Industry, September 2023] [zetasurgical.com]. Publicly reported differentiation rests less on a new modality than on workflow, portability, and deployment speed, including the company's claim that its systems can support outpatient, emergent, and clinic-based use cases that incumbent neurosurgical navigation platforms have not always targeted as directly [Healthcare Discovery, July 2026] [zetasurgical.com].
The founding team is unusually aligned to the clinical problem set: CEO José María Amich and CTO Raahil Sha are Harvard graduates, and co-founder William Gormley is a neurosurgeon with leadership roles in neurosurgical innovation at major Boston institutions, which gives the company credible technical and clinical roots even at seed stage [Design Industry, September 2023] [Doximity] [Mr. Jose Maria Amich | Author | University of Cambridge, retrieved 2026]. That matters here because adoption in image-guided neurosurgery typically turns on physician trust, workflow integration, and evidence generation as much as on software claims alone [Design Industry, September 2023] [Healthcare Discovery, July 2026].
On the capital side, the best-supported public record shows a $250,000 pre-seed and a $5.2 million seed led by Innospark Ventures, with participation from Y Combinator, TSVC, Plug and Play Ventures, and Trevor Fetter; other higher total-funding figures appear in secondary databases but are not as cleanly corroborated [TechCrunch, March 2022] [PR Newswire, March 2022] [Crunchbase]. The business model is hardware plus software, which can support defensibility if the company wins procedural adoption, but it also means the next 12 to 18 months likely hinge on FDA clearance expansion, named clinical deployments, and proof that early traction, including reported 2024 revenue of $2 million and later TMS commercialization milestones, can translate into repeatable sales motion rather than isolated wins [How Zeta Surgical hit $2M revenue with a 13 person team in 2024, retrieved 2026] [Yahoo Finance, July 2026] [zetasurgical.com].
Partially corroborated -- Core company, team, and 2022 funding facts are corroborated by TechCrunch, PR Newswire, and trade coverage; several product-performance and later commercialization details rely on company materials or single-source reporting.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Total disclosed approximately $7,000,000 (estimated) |
Inside the Company
PUBLIC
The core facts here are straightforward, and the chronology matters more than the pitch. Zeta Surgical is a Boston-based medical technology company founded in 2018, focused on navigation and robotics for neurosurgery and neurotherapeutics [Crunchbase]. Its public company materials describe the business around neuronavigation and related systems, while Crunchbase places the company in Boston and dates the founding to 2018 [Crunchbase] [zetasurgical.com].
The first clear public financing milestone came in March 2022, when the company emerged from stealth alongside a $5.2 million seed round led by Innospark Ventures [zetasurgical.com]. Crunchbase also records backing from Y Combinator, Plug and Play Ventures, TSVC, and Trevor Fetter, which is consistent with the company’s early investor base as presented across its public profile [Crunchbase].
Public milestones since then point to a company moving from platform formation toward regulatory and commercial validation. On its website, Zeta Surgical has announced FDA 510(k) clearance expansion for the Zeta Navigation System in May 2026 and later disclosed commercial activity around its TMS Navigation System in 2026, including first deployment news and additional clearance-related updates for TMS products [zetasurgical.com]. Taken together, the public record supports a progression from founding in 2018, to seed financing in 2022, to a more active FDA and deployment cadence by 2026 [Crunchbase] [zetasurgical.com].
Partially corroborated -- Confirmed primarily by Crunchbase and company website; chronology is coherent, but several milestone details rely on company-issued announcements.
Under the Hood
Reported and inferred
Zeta Surgical’s product story is unusually specific for a company at this stage: it is not selling general surgical software, but a navigation and robotics stack aimed at cranial procedures and neurotherapeutics where setup speed and positional accuracy matter. Public materials describe the Zeta Navigation System as a mixed-reality and computer-vision platform for minimally invasive cranial procedures, built around markerless image guidance rather than conventional fiducial markers [TechCrunch, March 2022] [Healthcare Discovery, July 2026]. Company materials say the system continuously aligns MRI or CT data with facial anatomy and provides live guidance during procedures, with intended use cases including ventriculostomy, brain biopsy, and other cranial interventions [zetasurgical.com] [iF Design].
The product line appears to have broadened from intra-cranial navigation into transcranial magnetic stimulation. Zeta’s public announcements describe a TMS Navigation System that provides real-time coil positioning and motion-aware tracking during treatment, and later a TMS Robotic System that received FDA 510(k) clearance in July 2026 [zetasurgical.com] [Yahoo Finance, July 2026]. A separate May 2026 company announcement states that the Zeta Navigation System received FDA 510(k) clearance expanding indicated access to brain tumor biopsies, hydrocephalus, and trigeminal neuralgia, while trade coverage in 2023 and 2026 points to a compact deployment model meant for operating rooms, emergency settings, and outpatient environments rather than only conventional neurosurgical suites [zetasurgical.com] [Design Industry, September 2023] [Medical Device Developments].
Evidence on performance is directionally interesting but still leans heavily on company-originated material. Zeta’s website cites a clinical study in external ventricular drain placement showing 100% single-pass catheter placement, 0% revision surgeries, and 0% adverse events versus worse freehand benchmarks, but those figures should be read as company-presented outcomes unless investors independently review the underlying study design and sample [zetasurgical.com]. The same caution applies to claims around submillimeter accuracy, guidance at 20 updates per second, and TMS session setup in under two minutes, which are consistent with the company’s positioning but not broadly corroborated in independent clinical literature within the materials reviewed [zetasurgical.com] [Healthcare Discovery, July 2026].
Claim stands unchecked -- This section mixes independent reporting on product category, FDA clearance, and deployment context with several material performance claims that are company-only or lightly corroborated [TechCrunch, March 2022] [Design Industry, September 2023] [Yahoo Finance, July 2026] [zetasurgical.com].
Market Research
PUBLIC
The market matters now because Zeta Surgical is selling into two parts of neuro care that are both under pressure to move high-precision procedures into faster, lower-friction settings: cranial navigation for minimally invasive interventions and navigated transcranial magnetic stimulation for outpatient neurotherapeutics [TechCrunch, March 2022] [Healthcare Discovery, July 2026].
Public source material does not provide a directly cited TAM, SAM, or SOM for Zeta Surgical itself, so the cleaner way to size the opportunity is through adjacent, explicitly labeled market proxies rather than unsupported estimates. The closest public analog in the source set is the stereotactic neuro-navigation market, where one industry report places Zeta among named participants and describes the category as focused on image-guided cranial procedures [Rise of Stereotactic Neuro-Navigation System Market & Key Players]. A second proxy is the navigated TMS market, where Zeta's FDA-cleared TMS systems are positioned for depression and other neurological conditions in outpatient clinics [Yahoo Finance, July 2026] [SOTA2, retrieved 2026]. Those proxies do not establish Zeta's addressable revenue, but they do frame a market that spans both capital equipment budgets in neurosurgery and procedure-volume economics in behavioral health.
The demand signals visible in public reporting are less about category size than about workflow friction. Zeta's core claim, repeated across coverage and company materials, is markerless image guidance that can be deployed outside a conventional operating room and used in outpatient, emergency, or interventional settings [TechCrunch, March 2022] [Design Industry, September 2023] [iF Design, retrieved 2026]. That matters because the incumbent neuronavigation workflow has often depended on more fixed infrastructure, fiducials, or OR-centric setup, while TMS clinics increasingly compete on throughput and consistency of coil placement [Healthcare Discovery, July 2026] [The Robotics Media, July 2026]. If those operational claims hold in broad clinical practice, the addressable demand may be shaped as much by site-of-care expansion as by share capture inside legacy neurosurgical suites.
Adjacent and substitute markets are also material here. On one side, Zeta competes with established surgical navigation platforms from Medtronic, Brainlab, and Elekta in image-guided cranial procedures [TechCrunch, March 2022]. On the other, its TMS products touch the wider neuropsychiatric treatment market, where clinics can still choose conventional TMS positioning workflows without robotic assistance, or route patients toward medication, psychotherapy, or other device-based interventions depending on indication and reimbursement [Yahoo Finance, July 2026] [PR Newswire, June 2026]. That creates a split market structure: hospital buyers may evaluate Zeta against navigation incumbents and capital planning cycles, while outpatient TMS buyers may underwrite the system against utilization, staffing efficiency, and patient throughput.
Regulation is not a side note in this category, it is a primary market-shaping force. Zeta's commercial progress in the public record is closely tied to FDA 510(k) clearances, first for its navigation platform and later for the TMS robotic system, with the 2026 clearance expanding indicated access across brain tumor biopsies, hydrocephalus, and trigeminal neuralgia according to the company and trade coverage [Design Industry, September 2023] [Medical Device Developments, retrieved 2026] [zetasurgical.com, May 2026] [Yahoo Finance, July 2026]. In practical terms, each clearance does two things at once: it enlarges the set of procedures a hospital or clinic can justify commercially, and it raises the evidentiary bar for smaller entrants that do not yet have comparable regulatory status. The macro constraint is that capital budgets in hospitals remain cyclical, while outpatient neurotherapeutics adoption can move faster if systems reduce setup time and training burden, though those workflow benefits are still supported mainly by company-linked evidence in this source set [TechCrunch, March 2022] [zetasurgical.com].
| Market lens | Public sizing or framing claim | Relevance to Zeta |
|---|---|---|
| Stereotactic neuro-navigation | Industry coverage identifies a neuro-navigation market with Zeta listed among participants [Rise of Stereotactic Neuro-Navigation System Market & Key Players] | Closest analog for cranial navigation demand |
| Navigated TMS | Trade and company-linked coverage positions Zeta's TMS systems for depression and other neurological conditions in clinics [SOTA2, retrieved 2026] [Yahoo Finance, July 2026] | Frames outpatient neurotherapeutics expansion |
| Site-of-care shift | Coverage repeatedly emphasizes use beyond the traditional operating room, including outpatient and emergent settings [TechCrunch, March 2022] [iF Design, retrieved 2026] | Suggests adoption may come from new care settings, not only incumbent replacement |
The public record here supports the direction of the market more clearly than its exact size. The important point is that Zeta sits at the intersection of two spending pools, neurosurgical navigation and outpatient TMS, and its commercial case appears to depend on making precision guidance practical in lower-friction care environments.
Partially corroborated -- Section relies on named public sources for market framing and regulatory context, but no independently corroborated third-party TAM, SAM, or SOM figures were available in the provided research.
Competition and Substitutes
MIXED Zeta Surgical is positioned less as a full-line neurosurgical platform vendor and more as a workflow challenger, trying to move image-guided cranial navigation into settings where incumbent systems can be slower to deploy or more infrastructure-heavy, according to company materials and trade coverage [TechCrunch, March 2022] [Healthcare Discovery, July 2026] [zetasurgical.com].
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Zeta Surgical | AI- and computer-vision-powered navigation and robotics for neurosurgery and targeted neurotherapeutics | Seed, $5.2M seed announced in March 2022, plus earlier $250k pre-seed | Markerless, real-time image guidance intended to support high-precision navigation outside a conventional operating room footprint | [TechCrunch, March 2022] [PR Newswire, March 2022] [Healthcare Discovery, July 2026] |
| Elekta | Established neurotechnology and radiosurgery incumbent | Public company | Installed base, clinical brand recognition, and broad hospital procurement familiarity in neuro-focused settings | [Competitive Landscape input] |
| Medtronic | Large medtech incumbent with neurosurgery adjacency | Public company | Distribution reach, capital base, and ability to bundle across hospital purchasing relationships | [Competitive Landscape input] |
| Brainlab | Surgical navigation incumbent | Private company | Deep specialization in navigation software and operating room workflow integration | [Competitive Landscape input] |
The field breaks into three practical layers. Incumbents such as Medtronic, Brainlab, and Elekta anchor the hospital side of the market, where procurement tends to reward installed base, service coverage, and integration with established neurosurgical workflows [Competitive Landscape input]. Zeta is approaching from a narrower flank, with public positioning around markerless cranial navigation, mixed reality, and TMS navigation rather than a broad enterprise neurosurgery stack [TechCrunch, March 2022] [Design Industry, September 2023] [zetasurgical.com].
Adjacent substitutes matter almost as much as direct peers. For some bedside, outpatient, or lower-acuity cranial procedures, the real comparison may be conventional freehand workflow, legacy frame-based or fiducial-based navigation, or sending the case into a higher-cost operating room pathway rather than adopting a new system [zetasurgical.com] [The Robot Report, March 2022]. That matters because Zeta does not need to displace every incumbent account at once. It only needs a credible case that certain procedures can be done with enough accuracy, less setup friction, and a lighter footprint.
The edge visible in public evidence is technical positioning paired with clinical-founder credibility, but it is still a perishable edge. The company has consistently framed its wedge around markerless, real-time guidance and point-of-care deployment, and later coverage ties that positioning to FDA-cleared navigation products and a TMS expansion path [TechCrunch, March 2022] [Design Industry, September 2023] [Yahoo Finance, July 2026] [zetasurgical.com]. The founding team also includes William Gormley, a practicing neurosurgeon, alongside Harvard-trained co-founders José María Amich and Raahil Sha, which should help with product design and early clinical trust [TechCrunch, March 2022] [Doximity] [Mr. Jose Maria Amich | Author | University of Cambridge, retrieved 2026].
Still, durability is not yet obvious from the public record. A markerless navigation approach can be differentiated at the product level, but incumbents with larger sales forces, service organizations, and procurement access can absorb or imitate workflow improvements faster than a seed-stage company can build nationwide distribution [PR Newswire, March 2022] [Healthcare Discovery, July 2026]. If Zeta's advantage rests primarily on setup speed and mobility, rather than on a protected data asset or a channel incumbents cannot reach, then the moat depends heavily on regulatory momentum and reference sites compounding before larger vendors respond.
The clearest exposure is against Medtronic and Brainlab in enterprise hospital accounts. Medtronic's advantage is breadth: it can approach neurosurgery buyers with existing purchasing relationships and a wider portfolio, which can matter more than a point solution when capital budgets tighten [Competitive Landscape input]. Brainlab's advantage is narrower but still material, because navigation buyers already familiar with its workflow may require Zeta to prove not just technical accuracy but integration, training, and support at a level comparable to an established platform vendor [Competitive Landscape input].
Elekta is a somewhat different kind of pressure. Where treatment planning, radiosurgery, and neuro-oncology relationships already run through Elekta, Zeta could find it harder to become the default vendor unless its point-of-care deployment model creates a clearly separate budget line or clinical pathway [Competitive Landscape input]. The company also appears less able, on public evidence, to compete as a full-service hospital systems supplier. Its most plausible opening remains procedure-specific adoption where incumbent systems are underused, impractical, or too resource-intensive for the setting.
Over the next 18 months, the most plausible competitive scenario is not category domination but segmentation. Zeta is the likely winner if the market rewards fast-deploying navigation in outpatient neurotherapeutics and lower-footprint cranial workflows, especially if recent FDA clearances convert into repeatable commercial deployments beyond early sites [zetasurgical.com] [Yahoo Finance, July 2026] [PR Newswire, June 2026]. Brainlab is the likely winner if buyers continue to prioritize proven integration inside conventional neurosurgical environments, where incumbent workflow familiarity can outweigh a newer architecture's deployment benefits [Competitive Landscape input].
A second-order scenario is that no single vendor wins outright, and the category fragments by care setting. In that case, Medtronic would remain strongest in large enterprise accounts, while Zeta could carve out a defensible niche in settings where mobility, setup time, and avoidance of traditional fiducials matter most [TechCrunch, March 2022] [Healthcare Discovery, July 2026]. That would still be a meaningful result for a company at this stage, but it implies the competitive battle is more about wedge expansion than head-on displacement.
Reasoned from indirect evidence -- Core company positioning is corroborated by TechCrunch, trade coverage, and company materials, but competitor-specific positioning and funding details for Elekta, Medtronic, and Brainlab were supplied only in structured inputs without independent source detail in this section.
Opportunity
PUBLIC
The prize here is not a single neurosurgery device sale, it is the chance to become a broadly deployed navigation layer for brain interventions that are moving out of the traditional operating room and into lower-cost, faster-deployment care settings [TechCrunch, March 2022] [Design Industry, September 2023] [Healthcare Discovery, July 2026].
The headline opportunity is straightforward: if Zeta Surgical can make markerless cranial navigation reliable, regulatorily expandable, and operationally easy to deploy, it could become default infrastructure for selected outpatient, bedside, and clinic-based neurological procedures where legacy navigation systems are too cumbersome or too tied to conventional operating-room workflows [TechCrunch, March 2022] [Design Industry, September 2023] [zetasurgical.com]. That outcome is still early, but it is not purely aspirational on the public record. The company emerged from stealth with a seed round led by Innospark Ventures in March 2022, has named strategic backers including Y Combinator and Plug and Play Ventures, and has since reported multiple FDA 510(k) clearances tied to cranial navigation and TMS workflows [TechCrunch, March 2022] [PR Newswire, March 2022] [Yahoo Finance, July 2026] [zetasurgical.com]. The evidence that matters is not size at this stage, it is scope expansion: the product story now spans emergency and minimally invasive cranial procedures, hospital IT integration, and commercial TMS deployment at HOPE Therapeutics clinics [Medical Device Developments] [PR Newswire, June 2026] [Healthcare Discovery, July 2026].
The public upside case breaks into a small number of identifiable paths rather than a single all-or-nothing bet. Each path depends on execution, but each also has a visible catalyst already in the record.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Outpatient cranial navigation standard | Zeta becomes a preferred navigation platform for selected cranial procedures performed outside the most resource-intensive OR environments | FDA 510(k) expansion into brain tumor biopsies, hydrocephalus, and trigeminal neuralgia broadens the addressable procedure set [zetasurgical.com] | Zeta's stated differentiation is rapid, markerless image guidance for emergent and outpatient settings, and third-party coverage of its 2023 clearance framed the system as deployable beyond conventional pinned workflows [Design Industry, September 2023] [iF Design] |
| TMS clinic operating system | Zeta's navigation and robotics stack becomes a standard upgrade for neuropsychiatric TMS clinics seeking more precise and repeatable treatment delivery | FDA 510(k) clearance for the Zeta TMS Robotic System in July 2026 and first commercial deployment at HOPE Therapeutics clinics [Yahoo Finance, July 2026] [PR Newswire, June 2026] | Public materials show a clinic-ready product sequence, first navigation then robotics, with named commercial deployment rather than lab-only validation [zetasurgical.com] [Healthcare Discovery, July 2026] |
| Hospital-to-network platform expansion | Zeta lands through flagship neurosurgical collaborators, then expands through accessory integrations and IT connectivity into broader health-system workflows | Reported compatibility with IZI Medical instruments and clearance allowing hospital IT network integration [Medical Device Developments] | This is plausible because medical navigation adoption often follows workflow fit, not just accuracy claims, and Zeta's public record increasingly emphasizes deployability, accessories, and data access rather than a single standalone box [Medical Device Developments] [Design Industry, September 2023] |
What compounding looks like is less a consumer-style network effect than a procedural and regulatory flywheel. A first wedge in cranial navigation can create more clinical evidence, more surgeon familiarity, and more accessory and site integrations, which in turn make adjacent indications easier to clear and sell [PR Newswire, March 2022] [zetasurgical.com]. The TMS line may matter disproportionately here. If the same computer-vision and positioning stack can serve both interventional neurosurgery and clinic-based neurotherapeutics, Zeta is not just adding SKUs, it is reusing a core navigation architecture across settings with very different sales motions [TechCrunch, March 2022] [Yahoo Finance, July 2026]. Public signs that this flywheel is starting are modest but real: FDA clearances have expanded over time, the company has moved from stealth financing to named commercial deployment, and it reported $2 million in 2024 revenue with a 13-person team according to an external profile [TechCrunch, March 2022] [PR Newswire, June 2026] [How Zeta Surgical hit $2M revenue with a 13 person team in 2024].
The size of the win is easiest to think about through category position rather than present scale. The named competitive set includes Elekta, Medtronic, and Brainlab, which places Zeta in markets where strategic value can accrue to workflow-defining navigation platforms rather than only to implant makers or capital equipment incumbents [TechCrunch, March 2022] [Crunchbase]. Public sources supplied here do not establish a clean market-size benchmark or directly comparable valuation multiple, so precision would be false. A reasonable upside framing is that if the "TMS clinic operating system" or "outpatient cranial navigation standard" scenario plays out, Zeta could become acquisition-relevant to large neurotechnology or medtech incumbents seeking a computer-vision navigation layer across procedures and care settings, potentially supporting a venture-scale outcome well above current disclosed funding levels (scenario, not a forecast) [TechCrunch, March 2022] [Yahoo Finance, July 2026] [Healthcare Discovery, July 2026]. That is the real opportunity on the public record: not a niche tool, but a platform that makes precision neuro-navigation easier to deploy wherever the next wave of neurological care is delivered.
Partially corroborated -- This section relies on public reporting from TechCrunch, PR Newswire, Design Industry, Yahoo Finance, Healthcare Discovery, and company materials. The growth scenarios are analytical interpretations built from confirmed financing, clearance, and deployment events, while the upside framing remains partly dependent on company-sourced product and regulatory claims.
Sources
Open sources
[TechCrunch, March 2022] TechCrunch, March 2022 | https://techcrunch.com/2022/03/10/zeta-surgical-comes-out-of-stealth-with-a-5-75m-raise-for-image-guided-surgery/
[Healthcare Discovery, July 2026] Zeta Surgical: neuronavigation without the pins | https://healthcarediscovery.ai/companies/zeta-surgical/
[PR Newswire, March 2022] Zeta Surgical Raises $5.2M in Seed Financing to Enhance Surgical Navigation with Robotics and Mixed Reality | https://www.prnewswire.com/news-releases/zeta-surgical-raises-5-2m-in-seed-financing-to-enhance-surgical-navigation-with-robotics-and-mixed-reality-301500348.html
[zetasurgical.com] ZETA | Next-gen neuronavigation | https://www.zetasurgical.com/
[Design Industry, September 2023] Zeta Surgical FDA Clearance | https://www.design-industry.com.au/news/zeta-surgical-fda-clearance
[Crunchbase] ZETA SURGICAL - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/zeta-surgical
[Doximity] Dr. William Gormley, MD | https://www.doximity.com/
[Mr. Jose Maria Amich | Author | University of Cambridge, retrieved 2026] Mr. Jose Maria Amich | Author | University of Cambridge | https://www.cambridge.org/core/search?filters%5BauthorTerms%5D=Jose%20Maria%20Amich
[How Zeta Surgical hit $2M revenue with a 13 person team in 2024, retrieved 2026] How Zeta Surgical hit $2M revenue with a 13 person team in 2024 | https://www.failory.com/cemetery/zeta-surgical
[Yahoo Finance, July 2026] Zeta TMS Robotic System received FDA 510(k) clearance on July 10, 2026 | https://finance.yahoo.com/
[iF Design] Zeta Cranial Navigation System | https://ifdesign.com/en/winner-ranking/project/zeta-cranial-navigation-system/615985
[Medical Device Developments] Zeta Navigation System received FDA 510(k) approval enabling deployment with new accessories and surgical kits | https://www.medicaldevice-network.com/news/zeta-surgical-fda-510k-clearance/
[SOTA2, retrieved 2026] Zeta TMS Navigation System | https://sota2.ai/
[The Robotics Media, July 2026] Zeta TMS Robotic System brings operating-room-level robotic accuracy to TMS clinics | https://www.theroboticsmedia.com/
[PR Newswire, June 2026] ZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics | https://www.prnewswire.com/news/zeta-surgical/
[Rise of Stereotactic Neuro-Navigation System Market & Key Players, retrieved 2026] Rise of Stereotactic Neuro-Navigation System Market & Key Players | https://www.linkedin.com/pulse/rise-stereotactic-neuro-navigation-system-market-key-players/
[The Robot Report, March 2022] Zeta Surgical raises $5.2M in seed funding | https://www.therobotreport.com/zeta-surgical-raises-5-2m-in-seed-funding/
Articles about Zeta Surgical
- Zeta Surgical's Markerless Navigation Moves Brain Surgery Out of the OR — The Boston startup's AI and computer vision platform, now FDA-cleared for TMS and cranial procedures, aims to make high-precision neuro-interventions faster and more accessible.